A phase 2 study of vudalimab, a pd-1 x ctla-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castrationresistant prostate cancer
Regular and Young Investigator Award Abstracts（2022）
关键词
prostate,vudalimab,chemotherapy,cancer,castration-resistant
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要